

1 **Title:** Genotype and defects in microtubule-based motility correlate with clinical severity in  
2 *KIF1A* Associated Neurological Disorder

3 **Authors:** Lia Boyle,<sup>1</sup> Lu Rao,<sup>2</sup> Simranpreet Kaur,<sup>3</sup> Xiao Fan,<sup>1,4</sup> Caroline Mebane,<sup>1</sup> Laura  
4 Hamm,<sup>5</sup> Andrew Thornton,<sup>6</sup> Jared T Ahrendsen,<sup>7</sup> Matthew P Anderson,<sup>7,8</sup> John Christodoulou,<sup>3</sup>  
5 Arne Gennerich,<sup>2</sup> Yufeng Shen,<sup>4,9</sup> Wendy K Chung<sup>1,10</sup>

6  
7 **Abstract:** *KIF1A* Associated Neurological Disorder (KAND) encompasses a recently identified  
8 group of rare neurodegenerative conditions caused by variants in *KIF1A*, a member of the  
9 kinesin-3 family of microtubule (MT) motor proteins. Here we characterize the natural history of  
10 KAND in 117 individuals using a combination of caregiver or self-reported medical history, a  
11 standardized measure of adaptive behavior, clinical records, and neuropathology. We developed  
12 a heuristic severity score using a weighted sum of common symptoms to assess disease severity.  
13 Focusing on 100 individuals, we compared the average clinical severity score for each variant  
14 with *in silico* predictions of deleteriousness and location in the protein. We found increased  
15 severity is strongly associated with variants occurring in regions involved with ATP and MT-  
16 binding: the P-loop, switch I, and switch II. For a subset of identified variants, we generated  
17 recombinant mutant proteins which we used to assess transport *in vivo* by assessing neurite tip  
18 accumulation, and to assess MT binding, motor velocity, and processivity using total internal  
19 reflection fluorescence microscopy. We find all patient variants result in defects in transport, and  
20 describe three classes of protein dysfunction: reduced MT binding, reduced velocity and  
21 processivity, and increased non-motile rigor MT binding. The molecular rigor phenotype is  
22 consistently associated with the most severe clinical phenotype, while reduced binding is  
23 associated with milder clinical phenotypes. Our findings suggest the clinical phenotypic  
24 heterogeneity in KAND likely reflects and parallels diverse molecular phenotypes. We propose a  
25 new way to describe KAND subtypes to better capture the breadth of disease severity.

---

<sup>1</sup> Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA

<sup>2</sup> Department of Anatomy and Structural Biology and Gruss Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA

<sup>3</sup> Murdoch Children's Research Institute, Parkville, Department of Pediatrics, University of Melbourne, Melbourne, Victoria 3052 AU

<sup>4</sup> Department of Systems Biology, Columbia University Irving Medical Center, New York, NY 10032

<sup>5</sup> Genetic & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

<sup>6</sup> Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA

<sup>7</sup> Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA

<sup>8</sup> Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; Boston Children's Hospital Intellectual and Developmental Disabilities Research Center, 300 Longwood Avenue, Boston, MA 02115, USA; Program in Neuroscience, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA

<sup>9</sup> Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA

<sup>10</sup> Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA

## 26 **Introduction**

27 *KIF1A* Associated Neurological Disorder (KAND) encompasses a recently identified group of  
28 rare progressive neurodegenerative conditions caused by pathogenic variants in *KIF1A*<sup>1-42</sup>.  
29 Variants can be inherited dominantly or recessively, with *de novo* variants associated with the  
30 most severe phenotypes. A novel feature of KAND is the large number of disease-causing  
31 variants, predominantly missense variants within the motor domain of the protein. In the existing  
32 literature, 71 variants have been described to date, and here we describe 48 additional variants<sup>2-</sup>  
33 <sup>34,37-39,41,43-45</sup>. More than 30% of individuals with KAND have private variants, and there are  
34 likely many more variants that remain to be identified. KAND has a broad phenotypic spectrum,  
35 which can include spasticity, neurodevelopmental delay, intellectual disability, autism,  
36 microcephaly, progressive spastic paraplegia, autonomic and peripheral neuropathy, optic nerve  
37 atrophy, cerebral and cerebellar atrophy, and seizures<sup>2-34,37-39,41,43-45</sup>.

38  
39 At the cellular level, *KIF1A* is a neuron-specific member of the kinesin-3 family of ATP-  
40 dependent microtubule (MT) molecular motor proteins. It predominately functions as a dimer  
41 and is responsible for anterograde transport of multiple cargos including synaptic vesicle  
42 precursors and dense core secretory vesicles on axonal and dendritic MTs<sup>46,47</sup>. The progression  
43 of kinesins along MTs requires ATP binding and hydrolysis, which cause conformational  
44 changes within the motor domain that power the forward motion of the motor<sup>46</sup>.

45  
46 *KIF1A* has been associated with two different autosomal recessive conditions: hereditary spastic  
47 paraplegia (HSP, MIM:610357) and hereditary sensory and autonomic neuropathy (HSAN,  
48 MIM:614213)<sup>2,3</sup>. Individuals with biallelic missense variants in the motor domain were found to

49 have HSP 30<sup>3</sup>, a condition consisting of peripheral nerve degeneration and severe distal sensory  
50 loss with distal motor involvement.

51

52 Heterozygous variants in *KIF1A* have been associated with NESCAV syndrome  
53 (Neurodegeneration and spasticity with or without cerebellar atrophy or cortical visual  
54 impairment, formerly mental retardation autosomal dominant 9) (MIM:614255), PEHO  
55 syndrome (Progressive encephalopathy with Edema, Hypsarrhythmia, and Optic atrophy) and  
56 with inherited cases of both simple and complicated HSP<sup>4-34,37-39,41,43-45</sup>. More recently,  
57 individuals with clinically diagnosed Rett Syndrome were identified with *de novo* *KIF1A*  
58 variants in individuals who did not have variants in the genes that predominantly cause Rett  
59 syndrome (*MECP2*, *CDKL5* and *FOXG1*)<sup>35,40</sup>.

60

61 Here we describe the natural history of KAND in 117 individuals with 68 different variants in  
62 *KIF1A*, provide detailed medical and neurodevelopmental phenotypes, and demonstrate a wide  
63 range of clinical severity with associated neuropathology on autopsy. We generated a KAND  
64 clinical severity score and correlate the clinical phenotype with genotype and molecular  
65 phenotype of the *KIF1A* motor.

66

## 67 **Subjects and Methods**

### 68 **Cohort**

69 This study was approved by the Institutional Review Board of Columbia University and  
70 informed consent was obtained for all participants. Individuals were referred by the family  
71 organization KIF1A.org. Clinical genetic test reports were reviewed to verify the diagnosis.  
72 Affected individuals or their parents or legal guardians completed a detailed structured medical  
73 history interview by phone and the Vineland Adaptive Behavior Scales, Third Edition (VABS-3)  
74 by computer. Clinical records and imaging data were reviewed to verify participant/caregiver  
75 reported history. Study data were managed using REDCap electronic data capture tools hosted at  
76 Columbia University Mailman School of Public Health<sup>11,12</sup>.

77  
78 In two cases, postmortem brain specimens were collected through the Autism Brain Net  
79 (<https://www.autismbrainnet.org/>). Consent for autopsy was obtained from the decedent's next of  
80 kin, which included provisions to save tissue for diagnostic and research purposes. The brain and  
81 spinal cord were removed and placed directly into 10% neutral buffered formalin fixed for 14  
82 days before gross examination and sectioning. Formalin fixed paraffin embedded tissue was  
83 sectioned and stained with H&E and luxol fast blue (H&E/LFB) prior to histologic examination  
84 by two neuropathologists.

### 86 **Genetic Data Analysis**

87 Individuals received clinical genetic testing from multiple clinical laboratories, with some  
88 individuals receiving whole exome sequencing and others panel gene testing. All *KIF1A* variants  
89 were re-interpreted centrally using ACMG guidelines<sup>48</sup>. Genetic reports were also reviewed for

90 any additional potentially contributing genetic factors that might contribute to the phenotype  
91 (Table S1, S2).

92

93 Variants were annotated with their population allele frequencies in Exome Aggregation  
94 Consortium (ExAC)<sup>49</sup>, Exome Sequencing Project (ESP; <http://evs.gs.washington.edu/EVS/>),  
95 1000 Genomes Samples<sup>50</sup>, and Genome Aggregation Database (gnomAD)<sup>49</sup>. Computational  
96 scores from REVEL and CADD version 1.4 were collected using ANNOVAR version  
97 2018Apr16. Biallelic predicted pathogenic variants that fit to an autosomal recessive inheritance  
98 pattern were identified. One individual was mosaic, and she was therefore excluded from the  
99 analyses to assess severity score, though her variant and her disease severity are shown in Figure  
100 1.

101

## 102 **Computational Methods**

103 To summarize clinical severity, we used numerical values to represent the clinical features of  
104 brain atrophy, optic atrophy, seizure, microcephaly, developmental delay, spasticity, and  
105 hypotonia: yes (1), no (-1) and not sure (0); and converted VABS composite score (adaptive  
106 behavior composite, communication, daily living skills, socialization and motor skills) to 1 for  
107 VABS scores <70, 0 for VABS scores between 70 and 85, and -1 for scores >85. We designed a  
108 heuristic severity score by weighted sum of the medical history data. We set the weight to 2 for  
109 brain atrophy, seizure, and microcephaly, and the rest were given a weight of 1. We further  
110 performed a principal component analysis (PCA) in individuals who had both medical history  
111 and VABS data. We characterized the genetic variants using functional region of the protein,  
112 particularly ATP and MT-binding regions.

113

## 114 **Construct Generation**

115 A recombinant *H. sapiens* KIF1A(1-393)-LZ-SNAPf-EGFP-6His construct containing the motor  
116 domain (amino acids 1-361), neck linker, neck coil domains, and a GCN4 leucine zipper (LZ) for  
117 stabilized dimerization was used for total internal reflection fluorescence (TIRF) microscopy. To  
118 generate this construct, a *R. norvegicus* KIF1A(1-393)-LZ-mScarlet construct obtained from Dr.  
119 Cassandra M. Ori-McKenney<sup>51</sup> (UC Davis) was modified as follows: KIF1A(1-393) was  
120 amplified by PCR and inserted into a vector with a SNAPf-tag, GFP-tag, and a 6xHis tag at the  
121 C-terminus. *H. sapiens* KIF1A(1-393) is identical to *R. norvegicus*, except for Ile 359, which is  
122 Val in *H. sapiens*. The NEB Q5® site-directed mutagenesis kit (New England Biolabs Inc.  
123 #E0554S) was therefore used to induce the I359V mutation to generate the *H. sapiens* KIF1A(1-  
124 393)-LZ-SNAPf-EGFP-6His construct. This KIF1A construct was then used as template to  
125 generate the 8 mutants using the Q5 mutagenesis kit. All constructs were confirmed by  
126 sequencing.

127

128 For neurite tip accumulation assays, a KIF1A(1-393)-LZ-3xmCit construct tagged with three  
129 tandem mCitrine (mCit) fluorescent proteins at the C-terminus was obtained from Dr. Kristen  
130 Verhey (University of Michigan, USA)<sup>52</sup>. The sequences of all the constructs used in this project  
131 were analyzed using SnapGene Viewer software (version 4.0.2;  
132 <https://www.snapgene.com/snapgene-viewer/>; GSL Biotech). Primers flanking individual  
133 specific variation site were designed using web-based QuikChange Primer Design Program  
134 available online ([www.agilent.com/genomics/qcpd](http://www.agilent.com/genomics/qcpd)) as per the software instructions. Patient  
135 specific variants were then introduced into the KIF1A(1-393)-3xmCit construct using

136 QuikChange lightning mutagenesis kit (Agilent technologies #210519) according to the  
137 manufacturer's instructions.

138

### 139 **Cell Lysate-Based Single-Molecule TIRF Assay**

140 Expression of KIF1A constructs in *E. coli* bacteria for single-molecule TIRF imaging is  
141 described in detail in the Supplemental Material. Following the generation of the *E. coli* cell  
142 lysate and its clearance by centrifugation, the cleared lysate was used for the initial single-  
143 molecule TIRF microscopy studies to determine whether the mutant KIF1A motors are mobile or  
144 not. The assay was performed as described before<sup>53</sup> except that a different assay buffer was used  
145 (see Supplemental Material). The lysate was diluted 100-fold in the assay buffer before the  
146 solution was flown into the slide chamber. The GFP-tag was used to track the motors. 600  
147 frames were acquired for each video with an acquisition time of 200 ms per frame. Kymographs  
148 were generated using Fiji.

149

### 150 **Protein Purification**

151 Further protein purification was performed as described in detail in the Supplemental Material.  
152 Following the incubation of the cleared *E. coli* cell lysate with an Ni-NTA resin, the resin was  
153 washed and then labeled with a SNAP-Cell® TMR-Star ligand. After another wash step, the  
154 protein was eluted with elution buffer and then flash frozen and stored at  $-80^{\circ}\text{C}$ . Before further  
155 usage, an MT-binding and-release (MTBR) assay was performed as previously described<sup>54</sup> with  
156 slight modifications (see Supplemental Material). The resulting protein solution was aliquoted  
157 and flash frozen as the "MTBR" fraction.

158

## 159 **Single-Molecule TIRF Assay With Purified Proteins**

160 For the WT and mobile mutant motors, MTBR fractions were used for the single-molecule TIRF  
161 assay and the dilutions were adjusted to an appropriate density of motors on MTs. The TIRF  
162 assay was performed as described above for the studies with the lysate, except TMR was used to  
163 track the motors. Images were analyzed using a home-build MATLAB software, and graphs  
164 were generated using Prism.

165

## 166 **Neurite Tip Accumulation**

167 SH-SY5Y (human neuroblastoma) cell-lines were grown in RPMI growth media (Sigma; Cat.  
168 no. R0883; with 3.7g/L NaHCO<sub>3</sub>, 2.0g/L glucose and 0.3g/L L-glutamine) supplemented with  
169 10% (vol/vol) FBS, 1X Pen-Strep at 37 °C in a humidified incubator and 5% CO<sub>2</sub>. The  
170 optimized density of SH-SY5Y cells ( $5 \times 10^4$  cells per well) was plated on sterile glass coverslips  
171 coated with 3.3% rat collagen (Corning; Cat. no.354236) and 2% matrigel (Corning; Cat. no.  
172 354248) in RPMI media without serum and antibiotics in a 12 well plate. After 24 hours, cells  
173 were transfected with the appropriate construct using Lipofectamine 2000 (Life Technologies;  
174 Cat. no. 11668019) according to the manufacturer's instructions. Neuronal differentiation of the  
175 transfected cells was then induced using RPMI differentiation media (RPMI supplemented with  
176 1% FBS, 1X Pen-Strep and 10μM retinoic acid (RA; Sigma; R2625)) that was refreshed every  
177 24 hours for three days. Cells were then washed with warm 1X phosphate buffer saline (PBS;  
178 137mM NaCl, 5.4mM KCl, 1.28mM NaH<sub>2</sub>PO<sub>4</sub>, 7mM Na<sub>2</sub>HPO<sub>4</sub>; pH 7.4), fixed in 4% (vol/vol)  
179 paraformaldehyde (PFA; Sigma; Cat. no. 158127) in PBS for 20 mins at room temperature  
180 before mounting on glass slides using Prolong Gold with DAPI (Thermo Fisher Scientific; Cat.  
181 no. P36935). Images were acquired using LSM780 fluorescence microscope with 40X objective

182 (zoom factor =2). ImageJ was used to quantify the mean florescence intensity (MFI) of the  
183 expressed fluorescent protein along the neurite length and cell body of cells. Statistical analysis  
184 on the average MFI was performed using Mann Whitney in Prism software (GraphPad). All  
185 experiments were performed in triplicate and repeated at least two times prior to data analysis.

186

## 187 **Structure Rendering**

188 All structures were rendered using Chimera<sup>48</sup>. The structure depicted is PDB 4UXP, *H. sapiens*  
189 KIF1A cryo-EM structure in the presence of AMP-PNP<sup>55</sup>. PDB 2HXF<sup>56</sup> (cryo-EM structure of  
190 the *M. Musculus* MT-bound KIF1A motor domain) was used to assign the secondary structure to  
191 the residues.

192

## 193 **Results**

### 194 **Summary of Clinical Phenotypes**

195 A summary of the clinical, radiological, and neurodevelopmental features of individuals is  
196 shown in Table 1, with specific variant and severity information available in Table S1. We report  
197 117 cases, of whom we have complete phenotypic data on 100 (Figure 1 and Table S1) While the  
198 majority of cases in our cohort had heterozygous *KIF1A* variants (115/117), we describe two  
199 biallelic individuals with asymptomatic carrier parents. In each biallelic instance there was one  
200 variant within the motor domain and one outside the motor domain. Among our heterozygous  
201 cases, the majority of *KIF1A* variants (64/115) were *de novo*, and 3 cases were inherited from an  
202 affected parent. Clinical information is not available for those affected parents. In some cases  
203 (48/115) parental testing results were not available. In a single instance, the affected individual  
204 was mosaic for the variant in blood.

205  
206 The most frequently observed symptoms in our cohort were hypotonia (84%, 84/100) and  
207 hypertonia or spasticity (81%, 81/100). Nearly all individuals had some degree of developmental  
208 delay and/or intellectual disability (92%, 92/100). Among those who had neuroimaging, the  
209 majority (58%, 54/93) had abnormal findings, most commonly cerebellar atrophy (35%, 33/93),  
210 abnormalities in the corpus callosum (11%, 10/93) and cerebral atrophy (6%, 6/93). Half of our  
211 cohort (50/100) had optic nerve atrophy or optic nerve hypoplasia, and there was a high  
212 prevalence of cortical visual impairment (20%, 20/100) and strabismus (26%, 26/100).

213  
214 Developmentally, most individuals were globally delayed, with an average VABS-III Adaptive  
215 Behavior Composite score of 60.6 (population mean of 100, SD of 15) (Table 1, Table S2).  
216 Frequently reported neurobehavioral diagnoses included autism (20%, 16/80), attention deficit  
217 hyperactivity disorder (24%, 19/80), anxiety (19%, 15/80) and obsessive compulsive disorder  
218 (5%, 4/80). We also saw some features commonly seen in Rett syndrome, including stereotypic  
219 hand movements like wringing or claspings (21%, 17/80), small extremities (34% 27/90), cold  
220 extremities (60%, 48/80), bruxism (35%, 28/80), abnormal laughing spells (15%, 11/80),  
221 scoliosis (14%, 14/100) and high pain tolerance (65%, 52/80).

222  
223 Seizures were common in our cohort, with 42% (42/100) reporting a history of seizures. Multiple  
224 seizure types were described, often in the same individual, with absence seizures as the most  
225 common in 29% (29/100) of the cohort overall and in 69% (29/42) of those with seizures.

226

227 We saw a number of features of dysautonomia. Just under half of individuals (46%, 37/80)  
228 experience difficulty with temperature regulation including sporadic fevers unrelated to illness.  
229 Gastrointestinal issues were common, with 40% (40/100) reporting gastroesophageal reflux  
230 disease (GERD), constipation (39%, 39/100) and diarrhea (17%, 17/100). Urinary retention and  
231 urinary incontinence were both reported. Many affected individuals experienced excessive  
232 salivation (26%, 21/80) or problems swallowing (29%, 23/80). Ten percent of the overall cohort,  
233 (10/100) required enteric nutritional support, in many cases due to the difficulty swallowing.

234  
235 We saw additional features not previously described, including a small number of individuals  
236 with abnormalities in the urogenital system. Irregularities in external genitalia were seen in both  
237 males and females (10/53 males, 4/47 females) and a few individuals had structural renal issues  
238 including renal agenesis, hydronephrosis, medullary nephrocalcinosis, and urinary reflux.  
239 Another feature not previously reported in KAND was short stature, which we observed in 11%  
240 (11/100) of our cohort. In three of those individuals, complete growth hormone deficiency was  
241 noted, which has been previously observed<sup>6,31,35</sup>.

242  
243 The condition is neurodegenerative, though the nature and course of decline varied by individual.  
244 Spasticity was progressive, and a number of individuals required surgical intervention: 15%  
245 (15/100) received tendon lengthening procedures. By the time they reached their 20s, many  
246 individuals were largely wheelchair dependent. When present, optic nerve atrophy also appeared  
247 to be progressive in most cases. While the loss of vision and of motor skills limited an  
248 individual's ability to participate in the activities of daily living over time, we largely did not see  
249 any cognitive regression.

250

## 251 **Neuropathological Findings**

252 At autopsy of a 13 year old female with a c.296C>T (p.Thr99Met) variant, the cerebellum was  
253 severely atrophic, most prominently in the midline, with relatively normal gyral patterning and  
254 development of the cerebrum (Figure 2A-F). Microscopic examination revealed severe cerebellar  
255 atrophy most prominent in the superior cerebellar vermis including a thin molecular layer, a  
256 depletion of Purkinje and internal granule cells, and Bergmann gliosis, and white matter pallor.  
257 Rare axonal spheroids were observed. The dentate nucleus as well as the inferior olivary nucleus  
258 of the medulla showed marked loss of neurons and severe reactive gliosis. Residual neurons in  
259 these areas were hypereosinophilic with pyknotic nuclei. Autopsy was also performed for a  
260 second patient with a *de novo* c.296C>T (p.Thr99Met) variant, a 5 year 9 month old female, and  
261 features were similar across both cases (Figure 2G-I).

262

## 263 **Computational results**

264 Our heuristic severity score approximated a normal distribution across all cases (Figure 3A).  
265 Using all available medical history and VABS data, we limited the analyses to age, sex, and  
266 common symptoms (>15% prevalence in the cohort) with <10% missing data. Principal  
267 component analysis (PCA) showed principal component 1 (PC1) was attributed mostly to the  
268 same symptoms used in the heuristic severity score as well as the VABS scores. PC2 is  
269 correlated with the age of disease onset. Earlier-onset cases were more likely to develop  
270 microcephaly and later-onset cases more often underwent musculoskeletal surgeries. The first  
271 three PCs explained 13.5%, 7.8%, and 5.8% respectively of the variance in the data.  
272 Additionally, we found that the heuristic severity score was highly correlated (R=0.84) with PC1

273 (Figure 3B). Since PCA is an unsupervised analysis, this high correlation supported the  
274 conclusion that the heuristic score is a good overall measurement of KAND severity.

275  
276 We hypothesized that severe cases have genetic variants with similar characteristics. We did not  
277 observe significant correlation between severity score and prediction score for variant  
278 deleteriousness such as REVEL and CADD, but all CADD scores were larger than 20 in this  
279 dataset. More importantly, the severity score was strongly associated with location in regions  
280 involved with ATP and MT-binding: the P-loop, switch I and switch II (Figure 3D). We found  
281 that 23 out of 28 (82%) of the variants seen in the most severe KAND cases (score  $\geq 5$ ) were  
282 located in the ATP and MT-binding regions, whereas only 14 out 24 (58.3%) of the least severe  
283 cases (score  $< 0$ ) had variants in these same regions (odds ratio = 1.4, p-value=0.003).

284 Additionally, cases with variants in the ATP and MT-binding regions have significantly higher  
285 severity scores (p=0.036; delta mean=1.6) than the ones with variants outside the ATP and MT-  
286 binding regions (Figure 3C).

287

### 288 **Effect of KAND Variants on Neurite Tip Accumulation**

289 To assess the effects of KAND variants on overall motor function of KIF1A, we expressed wild  
290 type (WT) and mutant KIF1A (1-393) tagged with three tandem copies of fluorescent  
291 monomeric citrine (mCit) in retinoic acid differentiated neuronal SH-SY5Y cells and measured  
292 the mean fluorescent intensity (MFI) at the cell body and along the neurite length. Consistent  
293 with previous work from our group and others, WT KIF1A accumulated at the distal tip of  
294 growing neurites in differentiated SH-SY5Y cells<sup>35,52</sup> (Figure 4). All KIF1A variants tested  
295 showed significant abilities to accumulate along the neurites of differentiated cells.

296

## 297 **Effect of KAND Variants on Velocity and Processivity**

298 To determine the effects of KAND variants on the velocity and processivity (the ability to take  
299 multiple steps before dissociating) of KIF1A, we employed TIRF microscopy and a tail-  
300 truncated, constitutively active KIF1A (*H. sapiens* aa 1-393) with a C-terminal leucine zipper  
301 (LZ) for stabilized dimerization as well as a SNAP-tag and a GFP tag. WT KIF1A and mutant  
302 motors were expressed in *E. coli* bacteria. Our recent work has shown that the velocity and force  
303 generation properties of KIF1A expressed in *E. coli* bacteria and mammalian cells are  
304 statistically indistinguishable<sup>57</sup>. A similar construct has also been used in other studies<sup>51,58,59</sup>.

305

306 Eight variants were selected and generated by mutagenesis. The positions of the mutations are  
307 illustrated in Figure 5. The mutants c.38G>A (p.Arg13His), c.296C>T (p.Thr99Met), c.751G>A  
308 (p.Gly251Arg), c.757G>A (p.Glu253Lys), and c.760C>T (p.Arg254Trp) are at or close to the  
309 ATP-binding site, while c.821C>T (p.Ser274Leu), c.914C>T (p.Pro305Leu), and c.946C>T  
310 (p.Arg316Trp) are near by the MT binding site specifically at the  $\beta$ -tubulin interaction interface  
311 (Figure 5A). For an initial assessment of the effects of the mutations, we used the *E. coli* cell  
312 lysate with the expressed *KIF1A* mutants without further purification and directly performed  
313 single-molecule TIRF microscopy studies. These initial experiments revealed that while the  
314 c.760 C>T (p.Arg254Trp), c.821 C>T (p.Ser274Leu), c.914C>T (p.Pro305Leu), and c.946C>T  
315 (p.Arg316Trp) mutants retained their ability to move processively, they appeared to have  
316 reduced run lengths (average distance traveled) (Figure 5B). In contrast, the c.38G>A  
317 (p.Arg13His), c.296C>T (p.Thr99Met), c.751G>A (p.Gly251Arg), and c.757G>A  
318 (p.Glu253Lys) mutants were completely unable to move (Figure 5B). We found c.296C>T

319 (p.Thr99Met), c.751G>A (p.Gly251Arg), and c.757G>A (p.Glu253Lys) attach to MTs in rigor  
320 while p.Arg13His lost its ability to bind to MTs (Figure 5B).

321  
322 To further quantify the motility behaviors of the motile mutant motors, c.760 C>T  
323 (p.Arg254Trp), c.821C>T (p.Ser274Leu), c.914C>T (p.Pro305Leu), and c.946C>T  
324 (p.Arg316Trp) were purified via Ni-NTA affinity purification and labeled with a SNAP-tag  
325 TMR ligand, followed by MT-binding and release affinity purification<sup>60</sup>. All four mutants  
326 exhibited reduced velocities. While WT KIF1A has an average velocity of  $2.10 \pm 0.03 \mu\text{m/s}$   
327 (mean  $\pm$  SEM), c.760 C>T (p.Arg254Trp), c.821C>T (p.Ser274Leu), c.914C>T (p.Pro305Leu),  
328 and c.946C>T (p.Arg316Trp) move at  $1.0 \pm 0.01 \mu\text{m/s}$ ,  $0.7 \pm 0.08 \mu\text{m/s}$ ,  $1.1 \pm 0.01 \mu\text{m/s}$ , and  
329  $0.8 \pm 0.01 \mu\text{m/s}$ , respectively (Figure 5C). In addition, all four mutants exhibited reduced  
330 processivities. While WT KIF1A is processive with a run length of  $13.2 \mu\text{m}$  (median value),  
331 c.760 C>T (p.Arg254Trp), c.821C>T (p.Ser274Leu), c.914C>T (p.Pro305Leu), and c.946C>T  
332 (p.Arg316Trp) exhibited run lengths of  $6.7 \mu\text{m}$ ,  $2.3 \mu\text{m}$ ,  $7.5 \mu\text{m}$ , and  $5.1 \mu\text{m}$ , respectively  
333 (Figure 5D).

334

### 335 **Discussion**

336 We describe the largest number of KAND individuals to date, including 48 novel missense  
337 variants, many of which were observed in single individuals. This suggests that we have not yet  
338 observed the full allelic spectrum in KAND. *KIF1A* is highly conserved. *KIF1A* has both fewer  
339 loss-of-function variants ( $o/e=0.07$ ) and fewer missense variants than would be expected  
340 ( $0.57$ )<sup>61</sup>. We observed both dominant and recessive inheritance patterns, with the majority of

341 KAND cases seen with heterozygous missense variants. Predicted loss-of-function variants were  
342 associated with milder disease than missense alleles.

343  
344 The majority of individuals diagnosed with *KIF1A*-associated HSAN had biallelic loss-of-  
345 function variants in the alternatively spliced exon 25b, though one individual had, in trans, one  
346 loss-of-function variant in exon 25b and a second loss-of-function in exon 45<sup>2</sup>. In all families  
347 with recessive *KIF1A*-associated HSAN, individuals heterozygous for a single loss-of-function  
348 variant were asymptomatic. There were notable differences between the individuals with *KIF1A*-  
349 associated HSAN who had homozygous variants in exon 25b and the single individual who was  
350 heterozygous for variants both in exon 25b and 45. All the homozygous individuals had disease  
351 onset in early adolescence (mean 9.7 years, SD 3.0 years) in contrast with the congenital disease  
352 seen in the compound heterozygous individual. Similarly, none of the homozygous individuals  
353 had any reported cognitive issues or issues with gait, while the compound heterozygous  
354 individual had delayed speech development with poor articulation and an IQ of 80 as well as  
355 short stature and difficulties with gait/ambulation requiring use of a wheelchair<sup>2</sup>. However, there  
356 was only one individual with HSAN who had a loss-of-function allele outside of exon 25b, so  
357 replication is required.

358  
359 Heterozygous loss-of-function variants including both premature termination and frameshift  
360 variants in *KIF1A* were associated with HSP. These individuals, some in their 60s at the time of  
361 report, all had normal cognition, normal MRIs, and no history of the visual problems or seizures  
362 common in our cohort<sup>32</sup>. If we hypothesize these loss-of-function variants result in nonsense

363 mediated decay of the mutant transcript, this suggests that up to a 50% reduction in protein can  
364 potentially be tolerated with minimal clinical symptoms for many decades.

365  
366 The clinical disease severity associated with missense variants in our study was much worse than  
367 any of the loss-of-function alleles, suggesting a dominant negative disease mechanism. Since  
368 KIF1A predominantly functions as a dimer, if the mutant and normal proteins dimerize to a  
369 similar degree, heterozygous individuals should only have 25% of the dimeric protein that is  
370 normal. Variants with decreased or no MT binding, like p.Arg13His and p.Ser274Leu (Figure  
371 S2), are associated with relatively milder disease, perhaps because mutant protein homodimers  
372 are unable to bind to MTs, and therefore cannot interfere globally with MT traffic, but only lead  
373 to decreased transport of KIF1A cargo. In contrast, variants including p.Gly251Arg and  
374 p.Glu253Lys, which bind tightly to the MT but are unable to engage in processive motion, were  
375 associated with the most severe disease. These rigor mutants likely lead to the most severe  
376 impact on all traffic along MTs, and may act as roadblocks resulting in an overall deficiency of  
377 cargo transport along the associated MT<sup>62</sup>. For alleles, like p.Arg254Trp, p.Pro305Leu, and  
378 p.Arg316Trp, where the mutant proteins bind to MTs but show reduced processivities and  
379 velocities (Figure 5C&D), *in vivo* these kinesins may affect MT transport globally and could  
380 interfere with all traffic along MTs.

381  
382 While a previous study suggested that the p.Arg254Trp and p.Arg316Trp mutants were  
383 incapable of binding to and moving along MTs, we found that these mutants were processive  
384 (the published results on the p.Arg13His, p.Thr99Met and p.Glu253Lys mutants agree with our  
385 findings)<sup>59</sup>. The reason for this discrepancy is unclear.

386

387 Consistent with previous reports, the majority of disease-associated *KIF1A* variants we report are  
388 located in the protein's motor domain. Using our clinical severity score, we observed that the  
389 most severe phenotypes were associated with variants clustered near the ATP and MT binding  
390 sites (Figure 5A). This includes the p.Thr99Met, p.Gly251Arg and p.Glu253Lys variants whose  
391 rigor phenotype likely represents defects in KIF1A's capacity to hydrolyze ATP. Our cohort was  
392 enriched for more severely affected individuals, but in the literature there were many individuals  
393 with missense variants in the motor domain with milder symptoms, more akin to pure HSP. It is  
394 likely these variants have an alternative mechanism of action, perhaps by hyperactivating motors,  
395 as was suggested in a recent study<sup>63</sup>.

396

397 While we observed some phenotype/genotype correlations, the correlations are imperfect, but  
398 this is not surprising. There are likely other contributors to the clinical phenotype including  
399 interacting genetic factors, prenatal and postnatal exposures, and the effects of therapeutic  
400 interventions. Our cohort included two sets of monozygotic twins, and in both instances, there  
401 were differences between the twins. In one family, one twin developed seizures in her teens  
402 while her sister did not develop seizures until her twenties. Many of these clinical features  
403 developed over time, and individuals in our cohort ranged in age in our cross-sectional study.  
404 With sufficient longitudinal data, we will assess how the scores and the disease change over  
405 time. An objective biomarker of neurodegeneration might provide a useful tool in conjunction  
406 with the clinical severity score.

407

408 The allelic heterogeneity of this condition is striking. We observed a range of severity across  
409 inheritance patterns, variant types, and variant locations. To assist with clearer communication  
410 about KAND, we propose three KAND subtypes: simple KAND, complex KAND, and HSAN  
411 KAND. We suggest distinguishing between individuals with only progressive lower extremity  
412 spasticity, ataxia, and peripheral neuropathy (simple KAND) and developmental delay,  
413 intellectual disability, seizures, optic nerve atrophy, and cerebellar atrophy (complex KAND).  
414 Complex KAND would include all individuals previously diagnosed with MRD9/NASCAV,  
415 PEHO, or *KIF1A*-related Rett syndrome. HSAN KAND would include individuals with variants  
416 in the alternatively spliced exon described previously. This new classification system could  
417 inform clinical management, and we suggest that all individuals with complex KAND would  
418 benefit from increased surveillance to detect the presence of seizures and progressive vision loss.  
419  
420 This study expands our understanding of the allelic spectrum and range of clinical phenotypes in  
421 KAND, and begins to address the molecular mechanisms of the disorder. With this broad  
422 phenotypic spectrum and the large number of variants, it is likely KAND is under recognized and  
423 under diagnosed. Better understanding of the phenotypic breadth and the disease subtypes could  
424 lead to improvements in diagnosis. As we move beyond diagnoses and work towards treatments,  
425 the ability to accurately predict prognosis and classify variants by molecular mechanism will  
426 facilitate the development of treatments.

427

#### 428 **Description of Supplemental Data:**

429 Supplemental data include 2 figures, 5 tables, and additional detailed methods.

430

431 **Acknowledgments:** We thank KIF1A.org for their ongoing partnership and Autism Brain Net  
432 for the collection of postmortem brain specimens. We thank Scott Robinson, Jennifer Shahar,  
433 Emily Horowitz, and Rachel Cogy for their assistance with this project. We thank Kristen  
434 Verhey for her assistance with optimizing the neurite tip accumulation and in vitro gliding  
435 assays. Molecular graphics generated with UCSF Chimera, developed by the Resource for  
436 Biocomputing, Visualization, and Informatics at the University of California, San Francisco,  
437 with support from NIH P41-GM103311. Grant support includes TL1TR001875 (LB),  
438 R01N114636 (LR, AG, WKC), KIF1A.org, UL1TR001873. Research conducted at the  
439 Murdoch Children’s Research Institute was supported by the Victorian Government’s  
440 Operational Infrastructure Support Program.

441

442 **Declaration of Interests:** All authors declare that they have no competing interests.

443

#### 444 **Web Resources**

445 OMIM, <http://www.omim.org>.

446

#### 447 **References**

- 448 1. Alfadhel M, Yong SL, Lillquist Y, Langlois S. Precocious puberty in two girls with PEHO  
449 syndrome: a clinical feature not previously described. *J Child Neurol*. 2011;26(7):851-  
450 857. doi:10.1177/0883073810396582.
- 451 2. Rivière J-B, Ramalingam S, Lavastre V, et al. KIF1A, an axonal transporter of synaptic  
452 vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. *American*  
453 *journal of human genetics*. 2011;89(2):219-230. doi:10.1016/j.ajhg.2011.06.013.

- 454 3. Erlich Y, Edvardson S, Hodges E, et al. Exome sequencing and disease-network analysis  
455 of a single family implicate a mutation in KIF1A in hereditary spastic paraparesis.  
456 *Genome Res.* 2011;21(5):658-664. doi:10.1101/gr.117143.110.
- 457 4. Hamdan FF, Gauthier J, Araki Y, et al. Excess of de novo deleterious mutations in genes  
458 associated with glutamatergic systems in nonsyndromic intellectual disability. *American*  
459 *journal of human genetics.* 2011;88(3):306-316. doi:10.1016/j.ajhg.2011.02.001.
- 460 5. Klebe S, Lossos A, Azzedine H, et al. KIF1A missense mutations in SPG30, an autosomal  
461 recessive spastic paraplegia: distinct phenotypes according to the nature of the mutations.  
462 *European journal of human genetics : EJHG.* 2012;20(6):645-649.  
463 doi:10.1038/ejhg.2011.261.
- 464 6. Okamoto N, Miya F, Tsunoda T, et al. KIF1A mutation in a patient with progressive  
465 neurodegeneration. *J Hum Genet.* 2014;59(11):639-641. doi:10.1038/jhg.2014.80.
- 466 7. Jamuar SS, Walsh CA. Somatic mutations in cerebral cortical malformations. *N Engl J*  
467 *Med.* 2014;371(21):2038-2038. doi:10.1056/NEJMc1411784.
- 468 8. Lee J-R, Srour M, Kim D, et al. De novo mutations in the motor domain of KIF1A cause  
469 cognitive impairment, spastic paraparesis, axonal neuropathy, and cerebellar atrophy.  
470 *Human mutation.* 2015;36(1):69-78. doi:10.1002/humu.22709.
- 471 9. Esmaeeli Nieh S, Madou MRZ, Sirajuddin M, et al. De novo mutations in KIF1A cause  
472 progressive encephalopathy and brain atrophy. *Ann Clin Transl Neurol.* 2015;2(6):623-  
473 635. doi:10.1002/acn3.198.

- 474 10. Ylikallio E, Kim D, Isohanni P, et al. Dominant transmission of de novo KIF1A motor  
475 domain variant underlying pure spastic paraplegia. *European journal of human genetics* :  
476 *EJHG*. 2015;23(10):1427-1430. doi:10.1038/ejhg.2014.297.
- 477 11. Citterio A, Arnoldi A, Panzeri E, et al. Variants in KIF1A gene in dominant and sporadic  
478 forms of hereditary spastic paraparesis. *Journal of neurology*. 2015;262(12):2684-2690.  
479 doi:10.1007/s00415-015-7899-9.
- 480 12. Ohba C, Haginoya K, Osaka H, et al. De novo KIF1A mutations cause intellectual deficit,  
481 cerebellar atrophy, lower limb spasticity and visual disturbance. *J Hum Genet*.  
482 2015;60(12):739-742. doi:10.1038/jhg.2015.108.
- 483 13. Megahed H, Nicouleau M, Barcia G, et al. Utility of whole exome sequencing for the  
484 early diagnosis of pediatric-onset cerebellar atrophy associated with developmental delay  
485 in an inbred population. *Orphanet J Rare Dis*. 2016;11(1):57. doi:10.1186/s13023-016-  
486 0436-9.
- 487 14. Hotchkiss L, Donkervoort S, Leach ME, et al. Novel De Novo Mutations in KIF1A as a  
488 Cause of Hereditary Spastic Paraplegia With Progressive Central Nervous System  
489 Involvement. *J Child Neurol*. 2016;31(9):1114-1119. doi:10.1177/0883073816639718.
- 490 15. Iqbal Z, Rydning SL, Wedding IM, et al. Targeted high throughput sequencing in  
491 hereditary ataxia and spastic paraplegia. Brusgaard K, ed. *PloS one*. 2017;12(3):e0174667.  
492 doi:10.1371/journal.pone.0174667.
- 493 16. Hasegawa A, Koike R, Koh K, et al. Co-existence of spastic paraplegia-30 with novel  
494 KIF1A mutation and spinocerebellar ataxia 31 with intronic expansion of BEAN and TK2

- 495 in a family. *Journal of the neurological sciences*. 2017;372:128-130.  
496 doi:10.1016/j.jns.2016.11.032.
- 497 17. Krenn M, Zulehner G, Hotzy C, et al. Hereditary spastic paraplegia caused by compound  
498 heterozygous mutations outside the motor domain of the KIF1A gene. *Eur J Neurol*.  
499 2017;42:174. doi:10.1111/ene.13279.
- 500 18. Cheon CK, Lim S-H, Kim Y-M, et al. Autosomal dominant transmission of complicated  
501 hereditary spastic paraplegia due to a dominant negative mutation of KIF1A, SPG30 gene.  
502 *Sci Rep*. 2017;7(1):12527. doi:10.1038/s41598-017-12999-9.
- 503 19. Roda RH, Schindler AB, Blackstone C. Multigeneration family with dominant SPG30  
504 hereditary spastic paraplegia. *Ann Clin Transl Neurol*. 2017;4(11):821-824.  
505 doi:10.1002/acn3.452.
- 506 20. Travaglini L, Aiello C, Stregapede F, et al. The impact of next-generation sequencing on  
507 the diagnosis of pediatric-onset hereditary spastic paraplegias: new genotype-phenotype  
508 correlations for rare HSP-related genes. *Neurogenetics*. 2018;19(2):111-121.  
509 doi:10.1007/s10048-018-0545-9.
- 510 21. Demily C, Lesca G, Poisson A, et al. Additive Effect of Variably Penetrant 22q11.2  
511 Duplication and Pathogenic Mutations in Autism Spectrum Disorder: To Which Extent  
512 Does the Tree Hide the Forest? *J Autism Dev Disord*. 2018;7(1):15050-15054.  
513 doi:10.1007/s10803-018-3552-7.

- 514 22. Lu C, Li L-X, Dong H-L, et al. Targeted next-generation sequencing improves diagnosis  
515 of hereditary spastic paraplegia in Chinese patients. *J Mol Med.* 2018;96(7):701-712.  
516 doi:10.1007/s00109-018-1655-4.
- 517 23. Samanta D, Gokden M. PEHO syndrome: KIF1A mutation and decreased activity of  
518 mitochondrial respiratory chain complex. *J Clin Neurosci.* October 2018.  
519 doi:10.1016/j.jocn.2018.10.091.
- 520 24. Tomaselli PJ, Rossor AM, Horga A, et al. A de novo dominant mutation in KIF1A  
521 associated with axonal neuropathy, spasticity and autism spectrum disorder. *J Peripher*  
522 *Nerv Syst.* 2017;95:590. doi:10.1111/jns.12235.
- 523 25. Yoshikawa K, Kuwahara M, Saigoh K, et al. The novel de novo mutation of KIF1A gene  
524 as the cause for Spastic paraplegia 30 in a Japanese case. *eNeurologicalSci.* 2019;14:34-  
525 37. doi:10.1016/j.ensci.2018.11.026.
- 526 26. Volk A, Conboy E, Wical B, Patterson M, Kirmani S. Whole-Exome Sequencing in the  
527 Clinic: Lessons from Six Consecutive Cases from the Clinician's Perspective. *Mol*  
528 *Syndromol.* 2015;6(1):23-31. doi:10.1159/000371598.
- 529 27. Elert-Dobkowska E, Stepniak I, Krysa W, et al. Next-generation sequencing study reveals  
530 the broader variant spectrum of hereditary spastic paraplegia and related phenotypes.  
531 *Neurogenetics.* 2019;20(1):27-38. doi:10.1007/s10048-019-00565-6.
- 532 28. Sun M, Johnson AK, Nelakuditi V, et al. Targeted exome analysis identifies the genetic  
533 basis of disease in over 50% of patients with a wide range of ataxia-related phenotypes.  
534 *Genet Med.* 2019;21(1):195-206. doi:10.1038/s41436-018-0007-7.

- 535 29. Muir AM, Myers CT, Nguyen NT, et al. Genetic heterogeneity in infantile spasms.  
536 *Epilepsy Res.* 2019;156:106181. doi:10.1016/j.eplepsyres.2019.106181.
- 537 30. Kashimada A, Hasegawa S, Nomura T, et al. Genetic analysis of undiagnosed ataxia-  
538 telangiectasia-like disorders. *Brain Dev.* 2018;41(2):150-157.  
539 doi:10.1016/j.braindev.2018.09.007.
- 540 31. Jacob D, Peter T, Nick G. A Novel Kif1a Mutation Causing a Neurodevelopmental  
541 Disorder. *Journal of neurology, neurosurgery, and psychiatry.* 2018;89(10):–A29.  
542 doi:10.1136/jnnp-2018-ABN.101.
- 543 32. Pennings M, Schouten MI, van Gaalen J, et al. KIF1A variants are a frequent cause of  
544 autosomal dominant hereditary spastic paraplegia. *European journal of human genetics :  
545 EJHG.* 2019;34:293–10. doi:10.1038/s41431-019-0497-z.
- 546 33. Xiaojing W, Yanyan M, Ruonan D, et al. Generation of a human induced pluripotent stem  
547 cell line (SDUBMSi001-A) from a hereditary spastic paraplegia patient carrying kif1a  
548 c.773C>T missense mutation. *Stem Cell Res.* 2020;43:101727.  
549 doi:10.1016/j.scr.2020.101727.
- 550 34. van de Warrenburg BP, Schouten MI, de Bot ST, et al. Clinical exome sequencing for  
551 cerebellar ataxia and spastic paraplegia uncovers novel gene-disease associations and  
552 unanticipated rare disorders. *European journal of human genetics : EJHG.*  
553 2016;24(10):1460-1466. doi:10.1038/ejhg.2016.42.

- 554 35. Kaur S, Van Bergen NJ, Verhey KJ, et al. Expansion of the phenotypic spectrum of de  
555 novo missense variants in kinesin family member 1A (KIF1A). *Human mutation*. July  
556 2020;humu.24079. doi:10.1002/humu.24079.
- 557 36. Raffa L, Matton M-P, Michaud J, Rossignol E, Décarie J-C, Ospina LH. Optic nerve  
558 hypoplasia in a patient with a de novo KIF1A heterozygous mutation. *Can J Ophthalmol*.  
559 2017;52(5):e169-e171. doi:10.1016/j.jcjo.2017.02.021.
- 560 37. Hosokawa S, Kubo Y, Arakawa R, Takashima H, Saito K. Analysis of spinal muscular  
561 atrophy-like patients by targeted resequencing. *Brain Dev*. November 2019.  
562 doi:10.1016/j.braindev.2019.10.008.
- 563 38. Spagnoli C, Rizzi S, Salerno GG, Frattini D, Fusco C. Long-term follow-up until early  
564 adulthood in autosomal dominant, complex SPG30 with a novel KIF1A variant: a case  
565 report. *Ital J Pediatr*. 2019;45(1):155–4. doi:10.1186/s13052-019-0752-5.
- 566 39. Kurihara M, Ishiura H, Bannai T, et al. A Novel de novo KIF1A Mutation in a Patient with  
567 Autism, Hyperactivity, Epilepsy, Sensory Disturbance, And Spastic Paraplegia. *Intern  
568 Med*. December 2019:3661–19. doi:10.2169/internalmedicine.3661-19.
- 569 40. Wang J, Zhang Q, Chen Y, Yu S, Wu X, Bao X. Rett and Rett-like syndrome: Expanding  
570 the genetic spectrum to KIF1A and GRIN1 gene. *Mol Genet Genomic Med*.  
571 2019;1(1):e968. doi:10.1002/mgg3.968.
- 572 41. Nemani T, Steel D, Kaliakatsos M, et al. KIF1A-related disorders in children: A wide  
573 spectrum of central and peripheral nervous system involvement. *J Peripher Nerv Syst*.  
574 2020;7(1):12527. doi:10.1111/jns.12368.

- 575 42. Guo Y, Chen Y, Yang M, et al. A Rare KIF1A Missense Mutation Enhances Synaptic  
576 Function and Increases Seizure Activity. *Frontiers in genetics*. 2020;11:61.  
577 doi:10.3389/fgene.2020.00061.
- 578 43. Langlois S, Tarailo-Graovac M, Sayson B, et al. De novo dominant variants affecting the  
579 motor domain of KIF1A are a cause of PEHO syndrome. *European journal of human*  
580 *genetics : EJHG*. 2016;24(6):949-953. doi:10.1038/ejhg.2015.217.
- 581 44. Raffa L, Matton M-P, Michaud J, Rossignol E, Décarie J-C, Ospina LH. Optic nerve  
582 hypoplasia in a patient with a de novo KIF1A heterozygous mutation. *Can J Ophthalmol*.  
583 2017;52(5):e169-e171. doi:10.1016/j.jcjo.2017.02.021.
- 584 45. Guo Y, Chen Y, Yang M, et al. A Rare KIF1A Missense Mutation Enhances Synaptic  
585 Function and Increases Seizure Activity. *Frontiers in genetics*. 2020;11:61.  
586 doi:10.3389/fgene.2020.00061.
- 587 46. Hirokawa N, Nitta R, Okada Y. The mechanisms of kinesin motor motility: lessons from  
588 the monomeric motor KIF1A. *Nature reviews Molecular cell biology*. 2009;10(12):877-  
589 884. doi:10.1038/nrm2807.
- 590 47. Tanaka Y, Niwa S, Dong M, et al. The Molecular Motor KIF1A Transports the TrkA  
591 Neurotrophin Receptor and Is Essential for Sensory Neuron Survival and Function.  
592 *Neuron*. 2016;90(6):1215-1229. doi:10.1016/j.neuron.2016.05.002.
- 593 48. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of  
594 sequence variants: a joint consensus recommendation of the American College of Medical

- 595 Genetics and Genomics and the Association for Molecular Pathology. In: Vol 17. Nature  
596 Publishing Group; 2015:405-424. doi:10.1038/gim.2015.30.
- 597 49. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in  
598 60,706 humans. *Nature*. 2016;536(7616):285-291. doi:10.1038/nature19057.
- 599 50. 1000 Genomes Project Consortium, Auton A, Brooks LD, et al. A global reference for  
600 human genetic variation. *Nature*. 2015;526(7571):68-74. doi:10.1038/nature15393.
- 601 51. Monroy BY, Sawyer DL, Ackermann BE, Borden MM, Tan TC, Ori-McKenney KM.  
602 Competition between microtubule-associated proteins directs motor transport. *Nat*  
603 *Commun*. 2018;9(1):1487. doi:10.1038/s41467-018-03909-2.
- 604 52. Hammond JW, Cai D, Blasius TL, et al. Mammalian Kinesin-3 motors are dimeric in vivo  
605 and move by processive motility upon release of autoinhibition. Schliwa M, ed. *PLoS*  
606 *Biol*. 2009;7(3):e72. doi:10.1371/journal.pbio.1000072.
- 607 53. Rao L, Berger F, Nicholas MP, Gennerich A. Molecular mechanism of cytoplasmic  
608 dynein tension sensing. *Nat Commun*. 2019;10(1):3332–17. doi:10.1038/s41467-019-  
609 11231-8.
- 610 54. Nicholas MP, Rao L, Gennerich A. An improved optical tweezers assay for measuring the  
611 force generation of single kinesin molecules. *Methods Mol Biol*. 2014;1136(33–38):171-  
612 246. doi:10.1007/978-1-4939-0329-0\_10.

- 613 55. Atherton J, Farabella I, Yu IM, et al. Conserved mechanisms of microtubule-stimulated  
614 ADP release, ATP binding, and force generation in transport kinesins. 2014.  
615 doi:10.2210/pdb4uxr/pdb.
- 616 56. Kikkawa M, Hirokawa N. High-resolution cryo-EM maps show the nucleotide binding  
617 pocket of KIF1A in open and closed conformations. *EMBO J.* 2006;25(18):4187-4194.  
618 doi:10.1038/sj.emboj.7601299.
- 619 57. Budaitis BG, Jariwala S, Rao L, Sept D, Verhey KJ, Gennerich A. Pathogenic Mutations  
620 in the Kinesin-3 Motor KIF1A Diminish Force Generation and Movement Through  
621 Allosteric Mechanisms. *Under revision.*
- 622 58. Soppina V, Verhey KJ. The family-specific K-loop influences the microtubule on-rate but  
623 not the superprocessivity of kinesin-3 motors. Steinberg G, ed. *Mol Biol Cell.*  
624 2014;25(14):2161-2170. doi:10.1091/mbc.e14-01-0696.
- 625 59. Guedes-Dias P, Nirschl JJ, Abreu N, et al. Kinesin-3 Responds to Local Microtubule  
626 Dynamics to Target Synaptic Cargo Delivery to the Presynapse. *Current Biology.* January  
627 2019. doi:10.1016/j.cub.2018.11.065.
- 628 60. Rao L, Hülsemann M, Gennerich A. Combining Structure-Function and Single-Molecule  
629 Studies on Cytoplasmic Dynein. *Methods Mol Biol.* 2018;1665(3):53-89.  
630 doi:10.1007/978-1-4939-7271-5\_4.
- 631 61. Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 human exomes and  
632 genomes reveals the spectrum of loss-of-function intolerance across human protein-coding  
633 genes. *bioRxiv.* January 2019:531210.

- 634 62. Gabrych DR, Lau VZ, Niwa S, Silverman MA. Going Too Far Is the Same as Falling  
635 Short: Kinesin-3 Family Members in Hereditary Spastic Paraplegia. *Front Cell Neurosci.*  
636 2019;13:409. doi:10.3389/fncel.2019.00419/.
- 637 63. Chiba K, Takahashi H, Chen M, et al. Disease-associated mutations hyperactivate KIF1A  
638 motility and anterograde axonal transport of synaptic vesicle precursors. *Proceedings of*  
639 *the National Academy of Sciences of the United States of America.* 2019;24:201905690.  
640 doi:10.1073/pnas.1905690116.

641

## 642 **Figure Titles and Legends**

643 **Figure 1. KIF1A variants by severity.** Shapes representing 251 affected individuals are shown  
644 below, including 114 individuals from our cohort and 137 individuals previously reported in the  
645 literature. Disease severity is shown for 98 of these cases from our cohort. Four affected  
646 individuals are not incorporated as their variants are not mappable below: this includes 3 variants  
647 affecting splicing (2 in our cohort, 1 in the literature) and one larger deletion from the literature.  
648 On top is the full-length protein, and on the bottom in a zoom in of the motor domain. Each icon  
649 represents a unique individual. The shape indicates inheritance and color indicates disease  
650 severity. In both the full-length protein and the motor domain, monoallelic variants are shown  
651 above and biallelic variants are shown below. Compound heterozygous individuals are  
652 represented by two separate triangles, one at each variant: those triangles have letters to indicate  
653 variant pairing. ATP and MT-binding regions in the motor domain are indicated by color.  
654 Splicing information only indicated for the alternatively spliced exon 25b.

655

656 **Figure 2. Neuropathological changes in two individuals with c.296C>T (p.Thr99Met)**

657 **KIF1A variant.** (A-F) Microscopic findings from a 13-year-old female (A-F) and a 6 year old  
658 female (G-I). Microscopic examination of H&E/luxol fast blue stained tissue sections reveal  
659 severely atrophic cerebellar folia (A, G) with thinned molecular layer, depletion of Purkinje  
660 cells, depletion of internal granule cells, Bergmann gliosis and pallor of the white matter  
661 (B,C,H). These changes are most severe in the superior aspect of the cerebellar vermis but are  
662 present in varying degrees throughout the cerebellum. Rare axonal spheroids are present (C, H,  
663 arrow) highlighted by neurofilament immunostain (I). The dentate nucleus (D,E) as well as the  
664 inferior olivary nucleus of the medulla (F) show marked loss of neurons and severe reactive  
665 gliosis. Residual neurons in these areas are hypereosinophilic with pyknotic nuclei. Scale bars: 1  
666 mm (20x magnification) A, D, G; 200 $\mu$ m (100x magnification) B, F; 100 $\mu$ m (200x  
667 magnification) C, E, H, I.

668  
669 **Figure 3. Clinical severity of 100 KAND cases.** (A) Distribution of heuristic severity score. (B)  
670 Scatter plot of principle components 1 and 3 color-coded by medical history derived severity  
671 scores. (C) Violin plot of medical history derived severity scores for individuals carrying  
672 mutations in or outside of ATP or MT binding regions. (D) Structure of the MT-bound KIF1A  
673 motor domain with severe residues and functional regions involved in ATP and MT binding  
674 highlighted (PDB: 4UXP, *H. sapiens* KIF1A CryoEM structure in the presence of AMP-PNP).  
675 Light gray: KIF1A; light gray; Blue:  $\alpha$ -tubulin; Pink:  $\beta$ -tubulin. Yellow: AMP-PNP; Red:  
676 residues mutated in most severe variants (p.Thr99, p.Glu148, p.Leu157, p.Val186, p.Ser214,  
677 p.Ser215, p.Gly251, p.Glu253, p.Arg254, p.Tyr306, p.Arg307, p.Arg316). The P-loop, Switch I  
678 and Switch II are shown in light blue, cyan, and teal respectively.

679

680 **Figure 4. Neurite tip accumulation in differentiated SH-SY5Y cells for KIF1A variants**

681 **seen in KAND individuals.** (A) Rat KIF1A (1-393) tagged with 3xmCit tag (green)

682 accumulated in the distal tips of differentiated SH-SY5Y cells in case of WT, but was localized  
683 closer to the cell body in cells transfected with KIF1A constructs containing individual variants.

684 (B) A significant reduction in the mean fluorescence intensity (MFI) along the neurite length

685 versus the cell body was observed in the 15 individual variants tested. Data were analyzed from

686 three independent experiments using a Mann-Whitney test (n=20 for each experiment) and is

687 plotted as mean  $\pm$  standard deviation. \*\*\*\* represents  $p < 0.0001$  versus WT.

688

689 **Figure 5. Sites of KIF1A mutations and motility analyses of dimeric KIF1A mutants.** (A)

690 Structure of the MT-bound KIF1A motor domain with the sites of mutated residues used for  
691 TIRF microscopy. Light gray: KIF1A; Blue:  $\alpha$ -tubulin; Pink:  $\beta$ -tubulin. Van der Waals sphere

692 represents AMP-PNP; red residues represent the mutation site (PDB: 4UXP, *H. sapiens* KIF1A

693 CryoEM structure in the presence of AMP-PNP). p.Arg13His, p.Thr99Met, p.Gly251Arg,

694 p.Glu253Lys, and p.Arg254Trp are at or close to the ATP binding site of KIF1A (left).

695 p.Ser274Leu, p.Pro305Leu, and p.Arg316Trp are close to the  $\beta$ -tubulin binding interface (right).

696 (B) Kymographs of KIF1A WT and mobile (top) and non-motile (bottom) mutant motors.

697 Diagonal lines in the kymograph represent KIF1A molecules that are moving over time. The

698 depicted scale bars are the same for all kymographs shown in this figure. (C) Velocities of

699 KIF1A WT and the mobile mutants. The green bars indicate the mean with SEM. Compared to

700 WT, all the mutants have reduced velocities. The WT has an average velocity of  $2.1 \pm 0.03 \mu\text{m/s}$

701 (mean  $\pm$  SEM) (n = 162), while p.Arg254Trp, p.Ser274Leu, p.Pro305Leu, and p.Arg316Trp

702 move at  $1.0 \pm 0.01 \mu\text{m/s}$  ( $n = 214$ ),  $0.7 \pm 0.08 \mu\text{m/s}$  ( $n = 24$ ),  $1.1 \pm 0.01 \mu\text{m/s}$  ( $n = 181$ ), and  $0.8$   
 703  $\pm 0.01 \mu\text{m/s}$  ( $n = 210$ ), respectively. (D) Run lengths of KIF1A WT and mutant motors. The  
 704 green bars indicate the median with quartile. All the mutants have reduced run lengths. The  
 705 WT's processivity has a median value of  $13.2 [8.3, 20.4] \mu\text{m}$ , while p.Arg254Trp, p.Ser274Leu,  
 706 p.Pro305Leu, and p.Arg316Trp have run lengths of  $6.7 [4.4, 11.6] \mu\text{m}$ ,  $2.3 [1.5, 3.5] \mu\text{m}$ ,  $7.5$   
 707  $[4.1, 13.8] \mu\text{m}$ , and  $5.1 [3.2, 7.7] \mu\text{m}$ , respectively.

708

709 **Table Title and Legend**


710 **Table 1: Phenotypic summary of KAND cases.** Clinical phenotypes of individuals with  
 711 variants in *KIF1A* are summarized by system. Table also includes summary data for 45  
 712 individuals from the literature with sufficient phenotypic information to allow for direct  
 713 comparison with our cohort.

|                     |                       | Our cohort |          | Literature cohort |         |
|---------------------|-----------------------|------------|----------|-------------------|---------|
| <b>Neurological</b> | Hypotonia             | 84%        | (84/100) | 38%               | (17/45) |
|                     | Hypertonia            | 81%        | (81/100) | 84%               | (38/45) |
|                     | Microcephaly          | 18%        | (18/100) | 18%               | (8/45)  |
|                     | Peripheral neuropathy | 27%        | (27/100) | 38%               | (17/45) |
| <b>Seizures</b>     | Overall               | 42%        | (42/100) | 38%               | (17/45) |
|                     | Grand mal             | 17%        | (17/100) |                   |         |
|                     | Petit mal/absence     | 29%        | (29/100) |                   |         |
|                     | Atonic drop seizures  | 9%         | (9/100)  |                   |         |

|                             |                                |     |          |     |         |
|-----------------------------|--------------------------------|-----|----------|-----|---------|
|                             | Infantile spasms               | 4%  | (4/100)  |     |         |
| <b>Cognitive/behavioral</b> | Developmental delay/ID         | 92% | (92/100) | 91% | (41/45) |
|                             | Autism                         | 20% | (16/80)  |     |         |
|                             | ADHD                           | 24% | (19/80)  |     |         |
|                             | Anxiety                        | 19% | (15/80)  |     |         |
|                             | Obsessive compulsive disorder  | 5%  | (4/80)   |     |         |
| <b>Gastrointestinal</b>     | GERD                           | 40% | (40/100) |     |         |
|                             | IBS                            | 2%  | (2/100)  |     |         |
|                             | Diarrhea                       | 17% | (17/100) |     |         |
|                             | Constipation                   | 39% | (39/100) |     |         |
| <b>Ophthalmic</b>           | Optic nerve atrophy/hypoplasia | 50% | (50/100) |     |         |
|                             | Cortical visual impairment     | 20% | (20/100) |     |         |
|                             | Strabismus                     | 26% | (26/100) |     |         |
|                             | Cataracts                      | 8%  | (8/100)  |     |         |
| <b>Urogenital</b>           | Renal agenesis                 | 1%  | (1/100)  |     |         |
|                             | Hydronephrosis                 | 1%  | (1/100)  |     |         |
|                             | Urinary reflux                 | 2%  | (2/100)  |     |         |
|                             | Medullary                      | 1%  | (1/100)  |     |         |

|                            |   |     |          |     |         |
|----------------------------|---|-----|----------|-----|---------|
|                            | nephrocalcinosis                            |     |          |     |         |
|                            | Small penis/scrotum                         | 17% | (9/53)   |     |         |
|                            | Hypospadias                                 | 2%  | (1/53)   |     |         |
|                            | Penile torsion                              | 2%  | (1/53)   |     |         |
|                            | Cosmetic irregularities in female genitalia | 9%  | (4/47)   |     |         |
| <b>Neuroimaging</b>        | Abnormal MRI finding                        | 58% | (54/93)  | 96% | (43/45) |
|                            | Cerebellar atrophy                          | 35% | (33/93)  | 65% | (28/43) |
|                            | Cerebral atrophy                            | 6%  | (6/93)   | 26% | (11/43) |
|                            | Corpus callosum atrophy/hypoplasia          | 11% | (10/93)  | 30% | (13/43) |
| <b>Additional features</b> | Short stature                               | 13% | (11/100) |     |         |
|                            | Complete absence of growth hormone          | 3%  | (3/100)  | 7%  | (3/45)  |
|                            | Scoliosis                                   | 14% | (14/100) | 9%  | (4/45)  |

714



## Variant key

### Disease severity

- ◊ Mild    ◊ Moderate    ◊ Severe
- ◊ Unknown    ◊ Literature

### Inheritance

- *De novo*    ◊ Dominant, inheritance unknown
- ◊ Dominant inherited    ▼ Recessive, heterozygous
- ▲ Recessive, homozygous










## Structure key




### ATP & MT-binding regions

- P-loop    ■ Switch I    ■ Switch II

### Protein domains

- Motor    ■ Neck coil    ■ Coiled-coil
- Forkhead associated    ■ Plextrin homology



**A****B****C****D**